Adding everolimus to carboplatin in advanced #TNBC reduced the risk of disease progression or death by 52% vs carboplatin alone By Amy Tiersten, MD, @RimapatelMD @IcahnMountSinai https://t.co/hQqlbQ3DHx #BCSM #HCC #Immunotherapy

📣What is the role of immune activation on the prognosis of early #TNBC if chemo is not given? We evaluated ~ 2,000 pts w eTNBC from 13 institutions around the globe to answer this. See our results published today in @JAMA_current https://t.co/N0fMyRWjP3

Excited to be staying at Mount Sinai as an Assistant Professor in Breast Medical Oncology! Thankful for the support of my incredible mentors, family, and friends. Looking forward to this next chapter!

Huge congratulations to @IcahnMountSinai @SinaiHemeOnc graduating fellows #2023 👏🎓🌟 Good luck on starting stellar careers!!

Finally out in @NEJM results from #POSITIVE trial showing that temporary interruption of #EndocrineTherapy to attempt #pregnancy is safe in #BreastCancer patients: this is wonderful news…super congrats @AnnPartridgeMD @etop_ibcsg et al! @OncoAlert #bcsm https://t.co/lGLX61heDV

Thank you @OncLive for the opportunity to share our findings on the relationship between race, Ki67, and Oncotype as well as palliative care use in elderly patients with breast cancer.

#VailWorkshop reunion at #SABCS2022 —great fun catching up friends/colleagues (missing a few in the 📸!) @AACR @ASCO @SABCSSanAntonio

Our expert, @RimapatelMD will give poster presentations on her latest #BreastCancer research at #SABCS22. Be sure to visit her to learn more. Find out more about @SABCSSanAntonio: https://t.co/4OtZvAg3QC @TischCancer

End-of-summer fellows & faculty picnic in Central Park replete with food, games, sun and camaraderie! 👏🏼 to our wellness committee - @AzziJacques @RimapatelMD @sridevirajeeve @BaileyFitz @orrinpail @RSJSheppard @XuejunWang @TischCancer @IcahnMountSinai

Updated results from #MONARCH3 at #ESMO22: addition of #abemaciclib to an aromatase inhibitor improves overall survival in endocrine sensitive advanced #bcsm (not significant at this interim analysis but to me clinically relevant: mOS=67 months, >1y gain) @OncoAlert @myESMO

JUST IN: @GileadSciences announced statistically significant OS from Phase 3 TROPiCS-02: SG antibody-drug conjugate prolongs OS in heavily-pretreated patients with HR+/HER2- metastatic breast cancer @DFCI_BreastOnc @OncoAlert, via @BusinessWire https://t.co/TLw8hBcr8p

Excited to share our work on the correlation between Oncotype and Ki67 using the IKWG categories. Important to consider when using Ki67 in clinical practice, especially to guide adjuvant abemaciclib @jsparano @MelanieKierMD @BZimmermanMD @TischCancer

Wrapping up an incredible week of clinical trial development at @AACR @ASCO #MCCR. Grateful to be have met and worked with these amazing oncologists! @quirogad @rleonferre @gandhi_shipra @FauziaRiaz @JingJiMD @JMcGuinnessMD @tarekmd91 @sridevirajeeve @lwumd323

Representing @IcahnMountSinai @TischCancer @SinaiHemeOnc at the @AACR @ASCO #MCCR22 "Vail" workshop. What a phenomenal week learning to write robust clinical trials! 📝 📸: Vail faculty @KarynAGoodman; Attendees Jr faculty Jon Feld, cofellows @RimapatelMD, @lwumd323, @tarekmd91

Enjoying our last day in #Vail for the @AACR @ASCO #MCCR workshop with these amazing women oncologists! @sridevirajeeve @KrithikaShanm @PrincessMark17

So proud of our PDG2 group @AACR @ASCO Vail #MCCR22 - Always an amazing experience, in an amazing place with amazing people 🫶. @oreganruth

Beaming as I watch @laura_huppert present at #ASCO22 as a fellow! This is a big deal 🙌🏼

.@RimapatelMD presented today at #ASCO22: Correlation of Ki67 working group prognostic risk categories with oncotype DX recurrence score in early #breastcancer. https://t.co/QK6DKW8rt4 @MountSinaiNYC @IcahnMountSinai

Great to be at #ASCO22 and share our findings on the correlation between Ki67 and Oncotype #bcsm @TischCancer @SinaiHemeOnc

Excited to reconnect @ASCO with this awesome crew of soon to be breast oncologists! 💃🏽 #womeninonc @laura_huppert @alainajkessler @RimapatelMD